Patient preferences for ovarian cancer treatment with PARP inhibitors
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study asks people with advanced ovarian cancer about their preferences for treatment with PARP inhibitors (a type of maintenance therapy). The goal is to learn what matters most to patients for their quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage 3 or 4 high-grade serous or endometrioid ovarian cancer (or are suspected to have it).
- You can give oral consent and fill out questionnaires in English.
- You are eligible to receive a PARP inhibitor (a type of maintenance therapy).
- You are willing to have HRD testing (a test that looks at how your cancer cells repair DNA).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well older adults (70+) with advanced ovarian cancer tolerate PARP inhibitors in real-world care. It aims to see if the standard dose works for this age group.
This study looks at how diet affects outcomes in people with ovarian cancer who are taking PARP inhibitors after initial treatment. Participation involves completing a food frequency questionnaire.
This study compares two PARP inhibitors (drugs that help repair DNA damage) combined with bevacizumab (an anti-angiogenic therapy) as maintenance treatment after chemotherapy in patients with advanced ovarian cancer that has a genetic vulnerability called HRD-positive. The goal is to see which combination works better at preventing cancer recurrence.
This trial tests whether a supervised exercise program combined with nutrition counseling can help women with advanced ovarian cancer who are taking PARP inhibitor maintenance therapy. It aims to improve quality of life and physical function during treatment.
This study looks for specific gene mutations in the blood of ovarian cancer patients who have a BRCA mutation and are starting first-line maintenance therapy with a PARP inhibitor called Olaparib. It aims to better understand how these mutations may affect treatment response.
This study looks at how women with advanced ovarian cancer respond to treatments based on whether their tumors have a specific DNA repair problem called homologous recombination deficiency (HRD). It aims to understand which treatments work best for different HRD test results.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.